EFSA beats off more Lactobacillus probiotic claims

By Shane Starling

- Last updated on GMT

Lactobacillus gasseri
Lactobacillus gasseri
The most researched group of probiotic strains – Lactobacillus – has been delivered yet another blow by the EU’s central science agency, which rejected digestive and vaginal health claims for nine individual strains.

The rejected strains submitted to the European Food Safety Authority (EFSA) under article 13.1 of the EU nutrition and health claims regulation (NHCR) were:

  • Lactobacillus crispatus​ BCCM/LMG P-17631 (ID1030, 2950)
  • Lactobacillus gasseri ​BCCM/LMG P-17632 (ID 2956)
  • Lactobacillus gasseri ​BCCM/LMG P-18137 (ID 2957, 2958)
  • Lactobacillus paracasei​ CNCM I-1687 (ID 2960, 2961)
  • Lactobacillus paracasei​ CNCM I-1688 (ID 2962, 2963)
  • Lactobacillus plantarum ​BCCM/LMG P-17630 (ID 2966, 2967)
  • Lactobacillus salivarius​ CNCM I-1794 (ID 2970, 2971)
  • A blend of Bifidobacterium animalis ​ssp. lactis ​Bf-6 and Lactobacillus johnsonii ​La-1 (ACD-1)(CLbA22) (ID 4231)

Perhaps most intriguingly, a claim that some of the above probiotic strains (2960, 2962, 2971) could increase IL-10 production and/or enhance the activity of natural killer cells ​was turned down primarily because it was not deemed a beneficial effect.

“The Panel notes that increasing IL-10 production and/or enhancing the activity of natural killer cells is not a beneficial physiological effect per se, but needs to be linked to a beneficial physiological or clinical outcome,”​ said EFSA’s Panel on Dietetic Products, Nutrition and Allergies (NDA).

That hadn’t been done, so the claim was rejected.

For many of the submitted strains’ ability to reduce gastro-intestinal discomfort​, the NDA said there were no intervention trials, “from which conclusions could be drawn for the scientific substantiation of the claim.”

For decreases in potentially pathogenic gastro-intestinal microorganisms ​the result was the same: No reliable intervention studies for the selected strains.

Improved lactose digestion ​for individuals with lactose maldigestion was similarly rejected.

‘Intestinal flora/digestive health’ ​was considered too general and non-specific a claim to be permissible under the NHCR.

Defence against vaginal pathogens was not backed by​ human intervention studies.

The NDA opinion can be found here.

Related news

Show more

Related products

show more

Unlock the business potential of the protein trend

Unlock the business potential of the protein trend

Content provided by Valio | 08-Feb-2024 | White Paper

Read our white paper to learn how to overcome taste and texture challenges in protein products — and how to commercialise the protein trend by making delicious...

Custom Microbiome Solutions for Dairy & Alt-Dairy Products

Custom Microbiome Solutions for Dairy & Alt-Dairy Products

Content provided by ADM: Innovation that Feeds the Future | 13-Oct-2023 | White Paper

Backed by clinical studies and perfect for use in dairy and alt-dairy applications alike, ADM’s Active Lifestyle probiotic blend, BPL1™ probiotic, and...

Consumers Want Dairy—and More!

Consumers Want Dairy—and More!

Content provided by ADM: Innovation that Feeds the Future | 06-Oct-2023 | White Paper

In the thriving dairy industry, you’re well aware of the surging demand for both dairy and non-dairy products.

Related suppliers